Emvena Therapeutics
Placenta-targeted mRNA medicines for maternal and fetal conditions.
The founders
MM
YK
KS
HS
AA
The company
Emvena Therapeutics is developing placenta-targeted mRNA medicines, using a lipid nanoparticle platform engineered to deliver mRNA preferentially to the placenta rather than other organs. Its lead programme encodes VEGF to treat preeclampsia, a pregnancy complication with no approved disease-modifying treatment.
mRNA and LNP delivery have moved from theory to approved products, but pregnancy has remained a near-blank space for drug development. A platform that targets the placenta specifically opens a category of maternal and fetal conditions that have long been treated with little more than bed rest and delivery.
The technology originates from the Mitchell Lab at the University of Pennsylvania, with the underlying work described in Nature. Emvena emerged from stealth in November 2026 as the first investment of the Penn-BioNTech Innovative Therapeutics Seed Fund.
The founding team spun the company directly out of the lab behind the published science, pairing academic origins with institutional backing from the PxB Fund. The company says its seed financing will carry the lead programme toward IND-enabling studies.
Who else is building in this space
Companies working on the same thing, at every stage.
Unicorn
Develops personalized immunotherapies with a focus on cancer medicine
Scale-up
Focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs
Scale-up
Using quantum-physics with AI to speed up the discovery of novel drug molecules
Unicorn
WaVe Life Sciences is leading the development of next-generation nucleic acids for therapeutic and diagnostic applications
The world’s first smart bracelet to precisely track your fertility, pregnancy and health – all while you sleep
AI software for early lung cancer diagnosis
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.